8-K Announcements
6Material company update
Feb 27, 2026·SEC
Material company update
Feb 19, 2026·SEC
Material company update
Dec 12, 2025·SEC
Prothena Corporation plc(PRTA)Earnings, Financials & Key Ratios
PRTA•NASDAQ
$11.18
$602M mkt cap·Price updated May 6, 2026
AboutProthena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.Show more
- Revenue$10M-92.8%
- EBITDA-$181M-17.7%
- Net Income-$244M-99.6%
- EPS (Diluted)-4.53-99.6%
- Gross Margin61.77%-38.2%
- EBITDA Margin-1867.6%-1542.6%
- Operating Margin-1905.82%-1566.6%
- Net Margin-2520.57%-2685.3%
- ROE-63.62%-172.6%
- ROIC-2099.82%-377.9%
- Debt/Equity0.05+121.9%
PRTA Key Insights
Prothena Corporation plc (PRTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 62.6%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 17.0% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRTA Price & Volume
Prothena Corporation plc (PRTA) stock price & volume — 10-year historical chart
Loading chart...
PRTA Growth Metrics
Prothena Corporation plc (PRTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.68%
5 Years62.56%
3 Years-43.57%
TTM-92.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-99.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-97.39%
Return on Capital
10 Years-26.78%
5 Years-21.35%
3 Years-34.19%
Last Year-47.05%
PRTA Recent Earnings
Prothena Corporation plc (PRTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 3/12 qtrs (25%)
Q1 2026Latest
Feb 19, 2026EPS
$0.44
Est $0.45
+2.2%
Revenue
$21,000
Est $1M
-98.4%
Q4 2025
Nov 6, 2025EPS
$0.67
Est $0.60
-11.7%
Revenue
$2M
Est $666,670
+262.2%
Q3 2025
Aug 4, 2025EPS
$1.86
Est $1.11
-67.6%
Revenue
$4M
Est $7M
-33.4%
Q2 2025
May 8, 2025EPS
$1.12
Est $0.92
-21.7%
Revenue
$3M
Est $15M
-81.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $0.44vs $0.45+2.2% | $21,000vs $1M-98.4% |
| Q4 2025 | Nov 6, 2025 | $0.67vs $0.60-11.7% | $2Mvs $666,670+262.2% |
| Q3 2025 | Aug 4, 2025 | $1.86vs $1.11-67.6% | $4Mvs $7M-33.4% |
| Q2 2025 | May 8, 2025 | $1.12vs $0.92-21.7% | $3Mvs $15M-81.6% |
Based on last 12 quarters of dataView full earnings history →
PRTA Peer Comparison
Prothena Corporation plc (PRTA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 |
Compare PRTA vs Peers
Prothena Corporation plc (PRTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRTA Income Statement
Prothena Corporation plc (PRTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 27.52M | 955K | 814K | 853K | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M |
| Revenue Growth % | 2508.44% | -96.53% | -14.76% | 4.79% | 23414.3% | -73.13% | 69.5% | 47.92% | -92.84% |
| Cost of Goods Sold | 134.55M | 101.18M | 50.84M | 74.88M | 0 | 0 | 0 | 0 | 3.7M |
| COGS % of Revenue | 488.92% | 10595.08% | 6245.21% | 8778.9% | - | - | - | - | 38.23% |
| Gross Profit | -107.03M▲ 0% | -100.23M▲ 6.4% | -50.02M▲ 50.1% | -74.03M▼ 48.0% | 200.58M▲ 370.9% | 53.91M▼ 73.1% | 91.37M▲ 69.5% | 135.16M▲ 47.9% | 5.98M▼ 95.6% |
| Gross Margin % | -388.92% | -10495.08% | -6145.21% | -8678.9% | 100% | 100% | 100% | 100% | 61.77% |
| Gross Profit Growth % | 9.66% | 6.35% | 50.09% | -48% | 370.94% | -73.13% | 69.5% | 47.92% | -95.57% |
| Operating Expenses | 182.77M | 143.66M | 35.67M | 38.7M | 128.6M | 185.46M | 282.41M | 289.72M | 190.54M |
| OpEx % of Revenue | 664.17% | 15043.46% | 4382.68% | 4537.28% | 64.12% | 344.05% | 309.08% | 214.36% | 1967.6% |
| Selling, General & Admin | 48.23M | 42.48M | 35.74M | 38.7M | 46.32M | 49.9M | 61.84M | 67.2M | 59.39M |
| SG&A % of Revenue | 175.25% | 4448.38% | 4390.17% | 4537.28% | 23.09% | 92.57% | 67.68% | 49.72% | 613.3% |
| Research & Development | 134.55M | 101.18M | 50.84M | 75.09M | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M |
| R&D % of Revenue | 488.92% | 10595.08% | 6245.21% | 8803.4% | 41.02% | 251.48% | 241.4% | 164.64% | 1392.52% |
| Other Operating Expenses | -2.35M | 2.74M | -50.9M | -75.09M | 0 | 0 | 0 | 0 | -3.7M |
| Operating Income | -155.25M▲ 0% | -158.85M▼ 2.3% | -85.7M▲ 46.1% | -112.73M▼ 31.5% | 71.97M▲ 163.8% | -131.56M▼ 282.8% | -191.04M▼ 45.2% | -154.56M▲ 19.1% | -184.56M▼ 19.4% |
| Operating Margin % | -564.17% | -16634.03% | -10527.89% | -13216.18% | 35.88% | -244.05% | -209.08% | -114.36% | -1905.82% |
| Operating Income Growth % | 2.68% | -2.32% | 46.05% | -31.55% | 163.84% | -282.78% | -45.21% | 19.09% | -19.41% |
| EBITDA | -152.19M | -155.64M | -84.13M | -111.22M | 73.09M | -130.81M | -190.11M | -153.67M | -180.86M |
| EBITDA Margin % | -553.03% | -16297.28% | -10335.75% | -13038.69% | 36.44% | -242.67% | -208.06% | -113.7% | -1867.6% |
| EBITDA Growth % | 3.13% | -2.27% | 45.94% | -32.2% | 165.72% | -278.98% | -45.33% | 19.17% | -17.69% |
| D&A (Non-Cash Add-back) | 3.07M | 3.22M | 1.56M | 1.51M | 1.11M | 744K | 928K | 893K | 3.7M |
| EBIT | -153.91M | -152.42M | -85.76M | -112.73M | 71.97M | -131.56M | -191.04M | -154.56M | -200.83M |
| Net Interest Income | -142K | 2.69M | 8.2M | 1.37M | 42K | 6.35M | 31.01M | 25.82M | 14.14M |
| Interest Income | 3.55M | 6.39M | 8.2M | 1.37M | 42K | 6.35M | 31.01M | 25.82M | 14.14M |
| Interest Expense | 3.69M | 3.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.35M | 2.74M | 8.4M | 1.87M | -54K | 5.95M | 30.56M | 25.63M | -16.27M |
| Pretax Income | -157.6M▲ 0% | -156.12M▲ 0.9% | -77.3M▲ 50.5% | -110.86M▼ 43.4% | 71.92M▲ 164.9% | -125.61M▼ 274.6% | -160.48M▼ 27.8% | -128.93M▲ 19.7% | -200.83M▼ 55.8% |
| Pretax Margin % | -572.71% | -16347.12% | -9496.07% | -12996.6% | 35.86% | -233.01% | -175.64% | -95.39% | -2073.82% |
| Income Tax | -4.37M | -470K | 379K | 283K | 4.95M | -8.66M | -13.45M | -6.62M | 43.26M |
| Effective Tax Rate % | 2.77% | 0.3% | -0.49% | -0.26% | 6.88% | 6.89% | 8.38% | 5.13% | -21.54% |
| Net Income | -153.24M▲ 0% | -155.65M▼ 1.6% | -77.68M▲ 50.1% | -111.14M▼ 43.1% | 66.97M▲ 160.3% | -116.95M▼ 274.6% | -147.03M▼ 25.7% | -122.31M▲ 16.8% | -244.09M▼ 99.6% |
| Net Margin % | -556.84% | -16297.91% | -9542.63% | -13029.78% | 33.39% | -216.95% | -160.92% | -90.49% | -2520.57% |
| Net Income Growth % | 4.29% | -1.57% | 50.09% | -43.08% | 160.26% | -274.62% | -25.72% | 16.81% | -99.57% |
| Net Income (Continuing) | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M | -244.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.07▲ 0% | -3.93▲ 3.4% | -1.95▲ 50.4% | -2.78▼ 42.6% | 1.38▲ 149.6% | -2.47▼ 279.0% | -2.76▼ 11.7% | -2.27▲ 17.8% | -4.53▼ 99.6% |
| EPS Growth % | 12.66% | 3.44% | 50.38% | -42.56% | 149.64% | -278.99% | -11.74% | 17.75% | -99.56% |
| EPS (Basic) | -4.07 | -3.93 | -1.95 | -2.78 | 1.51 | -2.47 | -2.76 | -2.27 | -4.53 |
| Diluted Shares Outstanding | 37.65M | 39.56M | 39.88M | 39.91M | 48.46M | 47.37M | 53.22M | 53.77M | 53.83M |
| Basic Shares Outstanding | 37.65M | 39.56M | 39.88M | 39.91M | 44.23M | 47.37M | 53.22M | 53.77M | 53.83M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PRTA Balance Sheet
Prothena Corporation plc (PRTA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 426.33M | 431.39M | 378.38M | 299.28M | 584.81M | 719.1M | 639.28M | 485.41M | 315.19M |
| Cash & Short-Term Investments | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M | 307.53M |
| Cash Only | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M | 307.53M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 240K | 2K | 68K | 15K | 13K | 62K | 5.16M | 0 | 0 |
| Days Sales Outstanding | 3.18 | 0.76 | 30.49 | 6.42 | 0.02 | 0.42 | 20.61 | - | - |
| Inventory | -240K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 1.35M | 766K | 1.71M | 3.49M | 1.17M | 7.66M |
| Total Non-Current Assets | 70M | 67.41M | 40.89M | 33.69M | 24.56M | 38.94M | 57.1M | 61.7M | 11.61M |
| Property, Plant & Equipment | 54.99M | 52.84M | 27.15M | 20.36M | 14.13M | 8.01M | 16M | 13.79M | 10.27M |
| Fixed Asset Turnover | 0.50x | 0.02x | 0.03x | 0.04x | 14.19x | 6.73x | 5.71x | 9.80x | 0.94x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 4.06M | 4.06M | 0 | 0 | 0 | 0 | 0 | 860K | 860K |
| Other Non-Current Assets | 6.9M | 4.87M | 3.79M | 1.69M | 3.35M | 12.72M | 7.21M | 3.81M | 482K |
| Total Assets | 496.33M▲ 0% | 498.8M▲ 0.5% | 419.27M▼ 15.9% | 332.98M▼ 20.6% | 609.37M▲ 83.0% | 758.03M▲ 24.4% | 696.38M▼ 8.1% | 547.11M▼ 21.4% | 326.8M▼ 40.3% |
| Asset Turnover | 0.06x | 0.00x | 0.00x | 0.00x | 0.33x | 0.07x | 0.13x | 0.25x | 0.03x |
| Asset Growth % | 7.9% | 0.5% | -15.94% | -20.58% | 83.01% | 24.4% | -8.13% | -21.44% | -40.27% |
| Total Current Liabilities | 37.37M | 14.93M | 17.71M | 25.85M | 33.45M | 50.15M | 56.89M | 48.5M | 40.84M |
| Accounts Payable | 13.63M | 1.47M | 1.24M | 4.12M | 3.69M | 9.27M | 25.39M | 7.77M | 5.88M |
| Days Payables Outstanding | 36.98 | 5.3 | 8.92 | 20.07 | - | - | - | - | 579.25 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.89M |
| Deferred Revenue (Current) | -857K | 110.24M | 0 | 0 | 7.66M | 11.44M | 0 | 8.85M | 2.66M |
| Other Current Liabilities | 1.72M | 837K | 322K | 516K | 405K | 503K | 2.13M | 29.27M | 29.42M |
| Current Ratio | 11.41x | 28.90x | 21.36x | 11.58x | 17.48x | 14.34x | 11.24x | 10.01x | 7.72x |
| Quick Ratio | 11.41x | 28.90x | 21.36x | 11.58x | 17.48x | 14.34x | 11.24x | 10.01x | 7.72x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.77M | 160.87M | 128.63M | 123.12M | 109.87M | 85.85M | 78.13M | 11.68M | 5.49M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.49M |
| Capital Lease Obligations | 51.52M | 49.9M | 17.84M | 12.33M | 6.39M | 0 | 10.72M | 8.23M | 5.49M |
| Deferred Tax Liabilities | -254K | -49.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 254K | 110.97M | 553K | 553K | 553K | 553K | 0 | 0 | -5.49M |
| Total Liabilities | 89.14M | 175.8M | 146.35M | 148.97M | 143.32M | 135.99M | 135.02M | 60.18M | 46.33M |
| Total Debt | 52.25M | 51.55M | 22.94M | 17.84M | 12.33M | 6.47M | 11.84M | 10.84M | 13.86M |
| Net Debt | -365.37M | -376.11M | -352.78M | -277.54M | -566.77M | -703.93M | -607M | -460.55M | -293.67M |
| Debt / Equity | 0.13x | 0.16x | 0.08x | 0.10x | 0.03x | 0.01x | 0.02x | 0.02x | 0.05x |
| Debt / EBITDA | - | - | - | - | 0.17x | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | -7.75x | - | - | - | - |
| Interest Coverage | -41.73x | -41.23x | - | - | - | - | - | - | - |
| Total Equity | 407.19M▲ 0% | 323M▼ 20.7% | 272.92M▼ 15.5% | 184.01M▼ 32.6% | 466.04M▲ 153.3% | 622.04M▲ 33.5% | 561.37M▼ 9.8% | 486.93M▼ 13.3% | 280.47M▼ 42.4% |
| Equity Growth % | 11.44% | -20.68% | -15.5% | -32.58% | 153.28% | 33.47% | -9.75% | -13.26% | -42.4% |
| Book Value per Share | 10.81 | 8.16 | 6.84 | 4.61 | 9.62 | 13.13 | 10.55 | 9.06 | 5.21 |
| Total Shareholders' Equity | 407.19M | 323M | 272.92M | 184.01M | 466.04M | 622.04M | 561.37M | 486.93M | 280.47M |
| Common Stock | 385K | 399K | 399K | 399K | 466K | 521K | 537K | 538K | 538K |
| Retained Earnings | -442.35M | -598M | -671.88M | -783.03M | -716.05M | -833M | -980.03M | -1.1B | -1.35B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -7.74M | -10.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRTA Cash Flow Statement
Prothena Corporation plc (PRTA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -131.18M | -28.28M | -52.97M | -80.36M | 92.61M | -108.82M | -133.91M | -150.05M | -163.58M |
| Operating CF Margin % | -476.7% | -2960.84% | -6507.25% | -9421.1% | 46.17% | -201.88% | -146.55% | -111.02% | -1689.18% |
| Operating CF Growth % | -11.87% | 78.45% | -87.33% | -51.72% | 215.23% | -217.51% | -23.05% | -12.06% | -9.02% |
| Net Income | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M | -244.09M |
| Depreciation & Amortization | 3.07M | 3.22M | 6.82M | 1.51M | 1.11M | 744K | 928K | 893K | 895K |
| Stock-Based Compensation | 26.76M | 27.01M | 23.59M | 22.01M | 24.66M | 31.32M | 40.91M | 45.96M | 37.64M |
| Deferred Taxes | -2.2M | -1.59M | -1.25M | -1.69M | 4.57M | -11.13M | -15.69M | -9.35M | 43.24M |
| Other Non-Cash Items | 1.59M | 4.28M | 0 | 5.46M | 5.69M | 6M | 7.5M | 2.69M | 2.91M |
| Working Capital Changes | -7.16M | 94.45M | -4.45M | 3.48M | -10.4M | -18.8M | -20.53M | -67.94M | -4.17M |
| Change in Receivables | -62K | 238K | 0 | 53K | 15K | 0 | -5.16M | 5.16M | 0 |
| Change in Inventory | -396.2M | 9.6M | 0 | 0 | 0 | 0 | -8.9M | 0 | 0 |
| Change in Payables | 147K | -25.63M | -78K | 7.73M | -492K | 11.87M | 22.86M | -18.3M | -15.78M |
| Cash from Investing | -3.52M | -1.73M | -547K | -196K | -575K | -464K | -2.77M | -298K | -138K |
| Capital Expenditures | -3.63M | -1.77M | -555K | -196K | -575K | -464K | -2.81M | -298K | -138K |
| CapEx % of Revenue | 13.18% | 185.13% | 68.18% | 22.98% | 0.29% | 0.86% | 3.08% | 0.22% | 1.43% |
| Acquisitions | 105K | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 105K | 39K | 8K | 0 | 0 | 0 | 37K | 0 | 0 |
| Cash from Financing | 165.4M | 40.04M | 228K | 215K | 190.33M | 241.46M | 45.1M | 1.55M | -139K |
| Debt Issued (Net) | -2.76M | -4.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 150.32M | 39.76M | 0 | 0 | 174.79M | 223.62M | 23.58M | -353K | -139K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -353K | 0 |
| Other Financing | 17.84M | 4.69M | 228K | 215K | 15.54M | 17.84M | 21.52M | 1.91M | 0 |
| Net Change in Cash | 30.7M▲ 0% | 10.04M▼ 67.3% | -53.29M▼ 630.8% | -80.34M▼ 50.8% | 282.36M▲ 451.4% | 132.17M▼ 53.2% | -91.58M▼ 169.3% | -148.79M▼ 62.5% | -163.86M▼ 10.1% |
| Free Cash Flow | -134.81M▲ 0% | -30.04M▲ 77.7% | -53.52M▼ 78.2% | -80.56M▼ 50.5% | 92.03M▲ 214.2% | -109.28M▼ 218.7% | -136.72M▼ 25.1% | -150.35M▼ 10.0% | -163.72M▼ 8.9% |
| FCF Margin % | -489.88% | -3145.97% | -6575.43% | -9444.08% | 45.88% | -202.74% | -149.63% | -111.24% | -1690.6% |
| FCF Growth % | -0.67% | 77.71% | -78.15% | -50.51% | 214.24% | -218.75% | -25.1% | -9.97% | -8.89% |
| FCF per Share | -3.58 | -0.76 | -1.34 | -2.02 | 1.90 | -2.31 | -2.57 | -2.80 | -3.04 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.18x | 0.68x | 0.72x | 1.38x | 0.93x | 0.91x | 1.23x | 0.67x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 294K | 0 | 1.58M | 1.37M | 580K | 2.66M | 1.55M | 3.17M | 0 |
PRTA Key Ratios
Prothena Corporation plc (PRTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -44.1% | -39.67% | -42.63% | -26.07% | -48.65% | 20.61% | -21.5% | -24.85% | -23.34% | -63.62% |
| Return on Invested Capital (ROIC) | -1203.55% | -325.18% | - | - | - | - | - | - | -439.41% | -2099.82% |
| Gross Margin | -11230.24% | -388.92% | -10495.08% | -6145.21% | -8678.9% | 100% | 100% | 100% | 100% | 61.77% |
| Net Margin | -15176.11% | -556.84% | -16297.91% | -9542.63% | -13029.78% | 33.39% | -216.95% | -160.92% | -90.49% | -2520.57% |
| Debt / Equity | 0.14x | 0.13x | 0.16x | 0.08x | 0.10x | 0.03x | 0.01x | 0.02x | 0.02x | 0.05x |
| Interest Coverage | -184.20x | -41.73x | -41.23x | - | - | - | - | - | - | - |
| FCF Conversion | 0.73x | 0.86x | 0.18x | 0.68x | 0.72x | 1.38x | 0.93x | 0.91x | 1.23x | 0.67x |
| Revenue Growth | -34.35% | 2508.44% | -96.53% | -14.76% | 4.79% | 23414.3% | -73.13% | 69.5% | 47.92% | -92.84% |
PRTA SEC Filings & Documents
Prothena Corporation plc (PRTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRTA Frequently Asked Questions
Prothena Corporation plc (PRTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prothena Corporation plc (PRTA) reported $9.7M in revenue for fiscal year 2025. This represents a 679% increase from $1.2M in 2010.
Prothena Corporation plc (PRTA) saw revenue decline by 92.8% over the past year.
Prothena Corporation plc (PRTA) reported a net loss of $244.1M for fiscal year 2025.
Dividend & Returns
Prothena Corporation plc (PRTA) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.
Prothena Corporation plc (PRTA) had negative free cash flow of $167.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRTA
Prothena Corporation plc (PRTA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates